

# Xin Hai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2567401/publications.pdf>

Version: 2024-02-01

23  
papers

178  
citations

1307594

7  
h-index

1199594

12  
g-index

23  
all docs

23  
docs citations

23  
times ranked

136  
citing authors

#	ARTICLE	IF	CITATIONS
1	HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 356-363.	2.8	29
2	AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide. <i>Toxicological Sciences</i> , 2018, 166, 219-227.	3.1	16
3	Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide. <i>Toxicology and Applied Pharmacology</i> , 2019, 379, 114687.	2.8	16
4	Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 229-236.	2.3	15
5	Polymorphisms in arsenic (+â€‰%3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3. <i>Archives of Toxicology</i> , 2020, 94, 1203-1213.	4.2	12
6	Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 371-378.	3.1	10
7	Speciation analysis of arsenic in urine samples from APL patients treated with single agent As2O3 by HPLC-HG-AFS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 171, 212-217.	2.8	9
8	Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide. <i>Toxicology Letters</i> , 2021, 347, 78-85.	0.8	8
9	Quantification of hydroxyurea in human plasma by HPLCâ€‰MS/MS and its application to pharmacokinetics in patients with chronic myeloid leukaemia. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 137, 213-219.	2.8	7
10	The correlation between plasma trimethylamine N-oxide level and heart failure classification in northern Chinese patients. <i>Annals of Palliative Medicine</i> , 2020, 9, 2862-2871.	1.2	7
11	Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 503-512.	3.1	7
12	Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4020-4026.	2.4	7
13	Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114201.	2.8	6
14	Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia. <i>Frontiers in Pharmacology</i> , 2021, 12, 647687.	3.5	5
15	Plasma fluoroacetic acid concentrations: Symptoms, hematological, and biochemical characteristics in patients with fluoroacetic acid poisoning in the emergency department. <i>Human and Experimental Toxicology</i> , 2020, 39, 634-641.	2.2	4
16	Improved HPLC method for the determination of ribavirin concentration in red blood cells and its application in patients with COVIDâ€‰19. <i>Biomedical Chromatography</i> , 2022, 36, e5370.	1.7	4
17	Sacubitril/valsartan protects against arsenic trioxide induced cardiotoxicity in vivo and in vitro. <i>Toxicology Research</i> , 2022, 11, 451-459.	2.1	4
18	Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 849-853.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Analysis of tizoxanide, active metabolite of nitazoxanide, in rat brain tissue and plasma by UHPLC-MS/MS. <i>Biomedical Chromatography</i> , 2020, 34, e4716.	1.7	3
20	Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	3
21	Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1173-1182.	3.1	2
22	Pharmacokinetics of cefoperazone/sulbactam in critically ill thrombotic thrombocytopenic purpura patients undergoing therapeutic plasma exchange. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1232-1239.	1.5	1
23	Developmental Changes in Potassium Channels in Low Threshold Myelinated Ah-type Vagal Ganglion Neurons in Rats. <i>Neuroscience</i> , 2020, 429, 256-263.	2.3	0